AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- Mylan Laboratories Inc. (NYSE:MYL) announced that it has entered into a settlement and license agreement ending its paclitaxel litigation.
The agreement was forged with Mayne Pharma (USA) Inc., formerly known as Faulding Pharmaceutical Co., and Tapestry Pharmaceuticals Inc., formerly known as Napro Biotherapeutics Inc.
In exchange for a one-time payment of $9 million, Mylan will receive a paid up irrevocable license from Mayne under all patents asserted in the litigation pending against Mylan in the U.S. District Court for the Western District of Pennsylvania.
In addition, the parties will promptly file stipulations of dismissal with prejudice with the U.S. District Court for the Western ...